person · Reporting owner
Gallagher Kathleen P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director · See Remarks | September 18, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atrium Therapeutics, Inc.
Report date September 18, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,729 |
Reported balance
After 2026-09-18 transaction · row 1
1 source rowRow 1 · 2026-09-18 · Tax withholding · Disposed 11,632 · Balance 119,729 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 80,303 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.12 · Expires 2031-04-25 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 22,321 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2032-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 13,829 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.65 · Expires 2032-07-17 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 9,244 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.65 · Expires 2032-07-17 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 13,352 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 27,584 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.24 · Expires 2033-08-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 42,480 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2034-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Disposition to issuer · Disposed 13,520 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.00 · Expires 2034-08-29 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-27 · Disposition to issuer · Disposed 16,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2035-01-05 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-27 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 22, 2026 20:17 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | Tax withholdingCommon Stock | 11,632 | $8.95 | $104,106.40 |
DisclosureSEC source: 0001193125-26-397944 · ownership.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,729 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 17:43 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantStock Option (Right to Buy) · Derivative | 205,000 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001193125-26-170914 · ownership.xml · derivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 205,000 shares Expires 2036-04-20 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 17:43 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantCommon Stock | 102,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-170914 · ownership.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,361 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $31.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 10 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,000 | Not disclosed Strike: $44.00 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 9 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2034-08-29 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,520 | Not disclosed Strike: $10.16 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 8 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,520 shares Expires 2034-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,480 | Not disclosed Strike: $8.24 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 7 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,480 shares Expires 2033-08-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,584 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 6 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,584 shares Expires 2033-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,352 | Not disclosed Strike: $16.65 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 5 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,352 shares Expires 2032-07-17 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,244 | Not disclosed Strike: $16.65 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 4 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,244 shares Expires 2032-07-17 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,829 | Not disclosed Strike: $14.70 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,829 shares Expires 2032-01-19 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,321 | Not disclosed Strike: $25.12 | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · derivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,321 shares Expires 2031-04-25 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:13 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 80,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082228 · ownership.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Tax withholdingCommon Stock | 8,030 | $71.87 | $577,116.10 |
DisclosureSEC source: 0001599901-25-000215 · wk-form4_1766150639.xml · nonDerivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,838 F3 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of restricted stock units on December 17, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Tax withholdingCommon Stock | 33,336 | $71.87 | $2,395,858.32 |
DisclosureSEC source: 0001599901-25-000215 · wk-form4_1766150639.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,868 F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 13:24 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 72,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000215 · wk-form4_1766150639.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,204 F1 · shares: Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 00:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 188 | $47.42 | $8,914.96 |
DisclosureSEC source: 0001599901-25-000171 · wk-form4_1756859427.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,204 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on August 30, 2025 and the sale of the resulting shares of common stock on September 2, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 22:02 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 911 | $30.24 | $27,548.64 |
DisclosureSEC source: 0001599901-25-000131 · wk-form4_1750284162.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:48 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,875 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001599901-25-000109 · wk-form4_1749070104.xml · derivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,596 Underlying: Common Stock · 5,875 shares Expires 2032-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:48 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,875 | $32.48 | $190,832.93 |
DisclosureSEC source: 0001599901-25-000109 · wk-form4_1749070104.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $33.22. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:48 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,875 | $16.65 | $97,818.75 |
DisclosureSEC source: 0001599901-25-000109 · wk-form4_1749070104.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| May 01, 2025 Filed May 2, 2025 23:55 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,875 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001599901-25-000097 · wk-form4_1746230127.xml · derivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,471 Underlying: Common Stock · 5,875 shares Expires 2032-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026. Read SEC document |
| May 01, 2025 Filed May 2, 2025 23:55 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,875 | $32.40 | $190,324.15 |
DisclosureSEC source: 0001599901-25-000097 · wk-form4_1746230127.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.99. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 2, 2025 23:55 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,875 | $16.65 | $97,818.75 |
DisclosureSEC source: 0001599901-25-000097 · wk-form4_1746230127.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 329 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001599901-25-000079 · wk-form4_1743713765.xml · derivative · entry 6 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,346 Underlying: Common Stock · 329 shares Expires 2032-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F4 · derivative.exercise_date: This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,546 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001599901-25-000079 · wk-form4_1743713765.xml · derivative · entry 5 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,829 Underlying: Common Stock · 5,546 shares Expires 2032-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on January 20, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2026. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 329 | $27.83 | $9,155.21 |
DisclosureSEC source: 0001599901-25-000079 · wk-form4_1743713765.xml · nonDerivative · entry 4 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.67 to $29.16. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 329 | $16.65 | $5,477.85 |
DisclosureSEC source: 0001599901-25-000079 · wk-form4_1743713765.xml · nonDerivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,546 | $27.83 | $154,330.76 |
DisclosureSEC source: 0001599901-25-000079 · wk-form4_1743713765.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.67 to $29.16. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:56 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,546 | $14.70 | $81,526.20 |
DisclosureSEC source: 0001599901-25-000079 · wk-form4_1743713765.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 23:17 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,875 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001599901-25-000061 · wk-form4_1741130257.xml · derivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,375 Underlying: Common Stock · 5,875 shares Expires 2032-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on January 20, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2026. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 23:17 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,875 | $29.41 | $172,807.25 |
DisclosureSEC source: 0001599901-25-000061 · wk-form4_1741130257.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.88 to $30.05. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 23:17 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,875 | $14.70 | $86,362.50 |
DisclosureSEC source: 0001599901-25-000061 · wk-form4_1741130257.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 22:01 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,875 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001599901-25-000045 · wk-form4_1738792857.xml · derivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,675 Underlying: Common Stock · 5,875 shares Expires 2032-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F3 · derivative.exercise_date: This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 22:01 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,875 | $32.16 | $188,918.26 |
DisclosureSEC source: 0001599901-25-000045 · wk-form4_1738792857.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.53 to $32.77. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 22:01 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,875 | $16.65 | $97,818.75 |
DisclosureSEC source: 0001599901-25-000045 · wk-form4_1738792857.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 01:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,629 | $30.16 | $169,775.71 |
DisclosureSEC source: 0001599901-25-000033 · wk-form4_1737680894.xml · nonDerivative · entry 4 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,554 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. F5 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.52 to $31.54. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,817 | $28.59 | $51,953.48 |
DisclosureSEC source: 0001599901-25-000033 · wk-form4_1737680894.xml · nonDerivative · entry 3 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,183 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F4 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.08. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 670 | $28.60 | $19,158.85 |
DisclosureSEC source: 0001599901-25-000033 · wk-form4_1737680894.xml · nonDerivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,000 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2025 and the sale of the resulting shares of common stock on January 21, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.47. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 24, 2025 01:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,295 | $28.59 | $37,024.05 |
DisclosureSEC source: 0001599901-25-000033 · wk-form4_1737680894.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,670 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:16 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $31.42 | $0.00 |
DisclosureSEC source: 0001599901-25-000017 · wk-form4_1736385384.xml · derivative · entry 2 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029. Read SEC document |
| January 06, 2025 Filed Jan 9, 2025 01:16 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000017 · wk-form4_1736385384.xml · nonDerivative · entry 1 Gallagher Kathleen P. · CIK 0002048409 · Chief Program Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,965 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.